New hope for kids with aggressive blood cancers: adding a targeted drug to standard chemo
NCT ID NCT01516580
Summary
This trial tested whether adding a targeted drug called rituximab to standard chemotherapy could improve survival for children and adolescents with high-risk B-cell lymphoma or leukemia. It involved 482 young patients aged 6 months to 18 years with advanced disease. The main goal was to see if the combination treatment helped patients live longer without their cancer returning or progressing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL NON HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
2nd Dept. of Pediatrics Semmelweis Univ.
Budapest, 1094, Hungary
-
Associazione Italiana di Ematologia ed Oncologia Pediatrica
Padua, 35128, Italy
-
Children Oncology Group Operations centres
Monrovia, Canada
-
Emma Children's Hospital
Amsterdam, 1105 AZ, Netherlands
-
Institut de Cancérologie Gustave roussy
Villejuif, 94805, France
-
Rectorat of Medical University
Wroclaw, Poland
-
Sociedad Española de Hematología y Oncología Pediátricas
Valencia, 46010, Spain
-
The University of Hong Kong (Clinical Trials Centre)
Hong Kong, China
-
University Hospitals Leuven
Leuven, 3000, Belgium
-
University of Birmingham
Birmingham, United Kingdom
Conditions
Explore the condition pages connected to this study.